Sartorius Stedim Biotech

DIM

FR0013154002

Medical Equipment, Supplies & Distribution

Market Closed - Euronext Paris Other stock markets 16:35:21 07/05/2024 BST			5-day change	1st Jan Change
208.2 ^EUR	+1.07%		+2.56%	-13.07%

04-23	SARTORIUS STEDIM BIOTECH : Barclays reaffirms its Neutral rating	ZD
04-22	Sartorius Stedim: in the red with brokerage comments	CF

SARTORIUS STEDIM BIOTECH : Barclays reaffirms its Neutral rating

April 23, 2024 at 07:27 am

In a research note published by Charles Pitman, Barclays gives a Neutral rating to the stock. The target price is lowered from EUR 250 to EUR 200.

Latest news about Sartorius Stedim Biotech

SARTORIUS STEDIM BIOTECH : Barclays reaffirms its Neutral rating	04-23	ZD
Sartorius Stedim: in the red with brokerage comments	04-22	CF
UBS Cuts Sartorius Stedim Biotech PT, Maintains at Neutral	04-22	MT
SARTORIUS STEDIM BIOTECH : Q1 24: A few positives despite the top-line miss	04-22
SARTORIUS STEDIM : UBS reduces target price	04-22	CF
Global markets live: DocMorris, Microsoft, Oracle, Micron, Netflix...	04-18
Transcript : Sartorius Stedim Biotech S.A., Q1 2024 Earnings Call, Apr 18, 2024	04-18
Transcript : Sartorius Aktiengesellschaft, Sartorius Stedim Biotech S.A., Q1 2024 Earnings Call, Apr 18, 2024	04-18
Sartorius and subsidiary Stedim under pressure after weak figures	04-18	DP
U.S. Futures, European Stocks Rise	04-18	DJ
Sartorius Stedim: Quarterly EPS more than halved	04-18	CF
Sartorius Stedim Biotech S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-18	CI
Sartorius Stedim Biotech Records Lower Q1 Attributable Net Profit, Sales Revenue	04-18	MT
Transcript : Sartorius Stedim Biotech S.A. - Shareholder/Analyst Call	03-26
SARTORIUS STEDIM BIOTECH : Jefferies remains its Buy rating	03-12	ZD
Berenberg: Sartorius Stedim Investors Await 'Several Strong Quarters' for Confidence Boost	02-16	MT
Sartorius gains despite halving dividend	02-09	DP
Sartorius Stedim Biotech S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	02-08	CI
Sartorius Stedim: dividend set for 2023	02-08	CF
Dpa-AFX Overview: COMPANIES from 07.02.2024 - 15:15	02-07	DP
Debt reduction: Sartorius sells shares - Stedim with capital increase	02-07	DP
Sartorius Stedim Biotech Shares Fall After Capital Increase	02-07	DJ
Sartorius Stedim Biotech Completes $1.3 Billion Capital Increase	02-07	DJ
Sartorius Stedim: private placement of 5.15 million shares	02-07	CF
Germany's Sartorius Raises EUR200 Million Via Share Issue	02-07	MT

Chart Sartorius Stedim Biotech

Duration

Period

More charts

Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. For next generation processes, Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of turning science into solutions on a daily basis. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany.

Sector

Medical Equipment, Supplies & Distribution

Calendar

16/05/2024 - Capital Markets Day

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

SARTORIUS STEDIM BIOTECH : Q1 24: A few positives despite the top-line miss

April 22, 2024 at 12:56 pm

More Strategies

Ratings for Sartorius Stedim Biotech

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

208.2 EUR

Average target price

251.3 EUR

Spread / Average Target

+20.72%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
SARTORIUS STEDIM BIOTECH	-13.07%	21.6B
ABBOTT LABORATORIES	-3.54%	184B
MEDTRONIC PLC	-0.58%	109B
BECTON, DICKINSON AND COMPANY	-2.74%	68.37B
DEXCOM, INC.	+4.84%	51.56B
CENCORA, INC.	+10.40%	44.69B
HOYA CORPORATION	+3.15%	41.49B
METTLER-TOLEDO INTERNATIONAL, INC.	+2.87%	26.75B
WEST PHARMACEUTICAL SERVICES, INC.	+4.61%	26.7B
TERUMO CORPORATION	+12.12%	25.68B

Other Medical Equipment, Supplies & Distribution